Skip to content 
Program
Wednesday, September 25, 2024
RNA systems biology
-
08:40 - 08:50 | Opening Remarks: Maria Carmo-Fonseca, Institute for Molecular Medicine (IMM), University of Lisbon
, Portugal - 08:50 - 09:30 | Keynote Lecture: Yoseph Barash, University of Pennsylvania, Philadelphia, PA, USA, "Finding where to target RNA for therapeutic intervention"
09:35 – 09:55
Manuel Irimia, Centre for Genomic Regulation, Barcelona, Spain
10:00 – 10:20
Katharina Höfer, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany
- 10:20 - 10:50 Break
10:50 – 11:10
Mary A. O’Connell, Central European Institute of Technology (CEITEC), Brno, Czech Republic
11:15 – 11:35
Martin Akerman, Envisagenics Inc. New York, USA
Poster Teasers
11:40 – 12:00
- 12:00 – 13:00 Lunch
The Interplay of Transcription and Splicing
13:00 – 13:20
Maria Carmo-Fonseca, Institute for Molecular Medicine (IMM), University of Lisbon, Portugal
miRNA-Based Logic Circuits Encoded on Self-Amplifying RNA for Highly Specific Cancer Cell Classification
13:25 - 13:45
Ron Weiss, Massachusetts Institute of Technology, USA
Development of FTO inhibitors for mRNA stabilization to treat AML cancer
13:50 - 14:10
Amir Mor, RNAble, Ness Ziona, Israel
RNA therapeutics development
14:15-14:20
Opening Remarks: Rotem Karni, The Institute for Medical Research Israel-Canada, Hebrew University- Hadassah Medical School, Israel
Keynote Lecture | Antisense Therapy for Diffuse Midline Glioma
14:20 - 15:00
Adrian R. Krainer, Cold Spring Harbor Laboratory, New York, USA
15:05 - 15:25
Annemieke Aartsma-Rus, Leiden University, The Netherlands
- 15:30 - 16:00 Break
REM-422, a small molecule that reprograms RNA processing to target MYB-driven hematological and solid cancers
16:00 - 16:20
Silvia Buonamici, Remix Therapeutics, Watertown, MA, USA
Oral splicing-regulation therapy for genetic diseases and cancer
16:25 - 16:45
Masatoshi Hagiwara, MD & PhD, Professor & Chairman, Graduate School of Medicine, Department of Drug Discovery Medicine, Kyoto University, Japan
Neutrophil-specific mRNA delivery - shooting at a moving target
16:50 - 17:10
Zvika Granot, Faculty of Medicine, Hebrew University, Jerusalem, Israel
Panel Discussion: Transforming Science into Practical Solutions: Insights from the CanceRNA Consortium
17:15 - 18:45
Tamar Raz, CEO, Hadasit Medical Research Services and Development, Jerusalem, Israel
This panel will delve into the critical business and commercialization strategies necessary to translate the CancerRNA Consortium’s research findings into tangible medical solutions and products. We will explore the primary barriers and challenges associated with commercializing RNA-based therapeutics, with a focus on innovations in cancer treatment. Additionally, the discussion will highlight how partners within the CancerRNA Consortium are addressing these challenges to advance effective new anti-cancer therapies.
Thursday, September 26, 2024
RNA therapeutics development (cont.)
Splice-switching Antisense Oligonucleotide Drug Discovery for Rare Neurodegenerative Diseases
08:50 - 09:10
Michelle L. Hastings, University of Michigan, Ann Arbor, MI, USA
Modulating mRNA stability for genetic diseases and cancer therapy
09:15 - 09:35
Rotem Karni, The Institute for Medical Research Israel-Canada, Hebrew University- Hadassah Medical School, Israel
RNA splicing in cancer
- 09:40 – 09:45 | Opening Remarks: Juan Valcarcel, Center for Genomic Regulation, Barcelona, Spain
- 09:45 – 10:25 | Keynote | Raul Mendez, Barcelona Institute for Research in Biomedicine, Barcelona, Spain, "Autism-like phenotype caused by a neuronal-microexon mis-splicing impairing kinetic stability of ribonucleoprotein condensates and regulation of mRNA translation in neurons"
- 10:30 - 10:50 Break
Building specificity of anti-tumor splicing inhibitors targeting SF3B1.
10:50 – 11:10
Juan Valcarcel, Centre for Genomic Regulation, Barcelona, Spain
11:15 – 11:35
Florian Heyd, Free University of Berlin, Germany
Alternative splicing of immune receptors as a regulatory mechanism
11:40 – 12:00
Michal Lotem, Hadassah Hebrew University Medical Center, Jerusalem, Israel
12:00 – 12:20
Niels Schaft, University of Erlangen, Erlangen, Germany
Poster Session
12:55 - 13:30
- 13:30 – 14:30 Lunch
14:55 – 15:15
Evelien Smits, University of Antwerp, Belgium
- 15:20 – 15:50 | Break
A-to-I RNA editing in cancer
15:50 – 16:10
Erez Levanon, Bar Ilan University, Ramat Gan, Israel
